Navigation Links
Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy
Date:4/3/2011

SEATTLE, April 4, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that the April 2011 edition of the peer reviewed journal, Leukemia & Lymphoma (April 2011; 52(4): 620–628) published results of a phase I/II clinical trial evaluating the effect of cyclophosphamide, pixantrone, vincristine, and prednisone ("CPOP") in treating patients with aggressive non-Hodgkin's lymphoma ("NHL") who relapsed following initial therapy with cyclophosphamide, doxorubicin, vincristine (Oncovin), and prednisone ("CHOP").  In the CPOP regimen, pixantrone substitutes for doxorubicin (H) in the CHOP regimen.  Peter Borchmann, M.D., of the University Hospital of Cologne, led the study.  CPOP produced high rates of complete remissions ("CR") and overall response rate ("ORR").  In some patients, these remissions were highly durable despite patients having relapsed after receiving CHOP and other multi-agent therapies.  

The study enrolled 35 patients in the phase I portion of the trial and 30 patients in the phase II portion of the trial. A major tumor response was reported for 80% and 73% of patients in phase I and II respectively, with 57% and 47% of the patients achieving a complete or unconfirmed CR. Median overall survival in the phase II portion of the trial was 17.9 months with four patients achieving notable long-term disease-free survival ranging from 55 to 77 months, despite in some cases having failed multiple prior regimens including stem cell transplantation. High response rates were also observed in the 43% of patients who had received prior rituximab as part of their front-line regimen (CHOP-R), with an ORR rate of 77% and CR rate of 54%. Myelosuppression was the most common toxicity. Side effects (grade 3/4) in phase I of the trial included febrile neutropenia (11%), grade 3/4 infections (3%), and cardiac failure (6%). In phase II of the trial, side effects (grade 3/4) included febril
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
2. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
3. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
4. Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 10, 2010
5. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
6. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
7. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
8. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
9. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... months endedChange %  30 September 201430 September 2013Turnover 546,011 , ... , 384,242 , 339,113 , 13.3 ... , 49.5 Medical Insurance Administration Service Income , ... Devices and Accessories Sales , 94,580 , 142,683 ... 2,917 , 9,219 , (68.4) Impairment Loss on ...
(Date:11/26/2014)... Nov. 26, 2014   Royal Philips ... announced expanded availability of its portfolio of ... wDR, MobileDiagnost Opta[i] , ProGrade and PrimaryDiagnost[ii]. With ... available in the U.S., and availability of all ... offers Philips, customers innovative solutions designed to meet ...
(Date:11/26/2014)... , Nov. 26, 2014 Lexicon Pharmaceuticals, ... the completion of previously announced concurrent financing transactions ... fees and estimated offering expenses, Lexicon anticipates net ...  The transactions consisted of: , a ... pursuant to a registration statement that has been ...
Breaking Medicine Technology:Golden Meditech Announces 2014 / 2015 Interim Results 2Golden Meditech Announces 2014 / 2015 Interim Results 3Golden Meditech Announces 2014 / 2015 Interim Results 4Golden Meditech Announces 2014 / 2015 Interim Results 5Golden Meditech Announces 2014 / 2015 Interim Results 6Golden Meditech Announces 2014 / 2015 Interim Results 7Golden Meditech Announces 2014 / 2015 Interim Results 8Philips expands global reach of diagnostic X-Ray solutions 2Philips expands global reach of diagnostic X-Ray solutions 3Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3
... at High,Risk , ,WASHINGTON, March 9, 2007 ... history of end-stage renal disease (ESRD), and,these individuals appear ... reports a study in the April Journal of,the American ... disease is more frequent in,African-Americans, who are also at ...
... Pharmaceuticals,Inc. (OTCBB:CGXP), a biopharmaceutical company focused on,infectious ... catheter,treated with a Ceragenin compound demonstrated virtually ... In the study, polyurethane catheters treated with ... along with an,untreated catheter. At day 21, ...
Cached Medicine Technology:Nearly 1 in 10 Americans Has A Relative With Kidney Failure 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3
(Date:11/28/2014)... The Alternative Health Therapies ... five years. The industry has been buoyed by ... either alternative to conventional Western medicine or complementary ... David Whytcross, “industry revenue has been further boosted ... insurance membership.” Meanwhile, improving economic conditions following the ...
(Date:11/28/2014)... 27, 2014 (HealthDay News) -- Planning on seconds at ... heartburn -- clinically known as gastroesophageal reflux disease (GERD) -- ... Jordan Josephson, an ear, nose and throat specialist at Lenox ... to help manage GERD on Thanksgiving: Pace ... least two small meals throughout the day. It,s also a ...
(Date:11/28/2014)... November 28, 2014 An inventor and dental ... on a patient’s filling and it was almost impossible to ... curing light," she said. , The patent-pending Access Light allows ... access to areas of the mouth, as well as avoids ... and safety. Easy to use and clean, it also helps ...
(Date:11/28/2014)... November 28, 2014 A newly released ... an overview of the influenza virus that will soon be ... , The article begins with a brief explanation of ... symptoms. It reminds families that children under the age of ... from chronic diseases, such as heart and lung diseases, asthma, ...
(Date:11/28/2014)... November 28, 2014 "Most of my life, ... to use crutches," said an inventor from Findlay, Ohio. "I ... way to support my foot, which inspired me to invent ... offer a convenient way to support an injured foot. The ... It eliminates the need for crutches. The design redistributes weight ...
Breaking Medicine News(10 mins):Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Don't Let Chronic Heartburn Spoil Your Thanksgiving Feast 2Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2
... gastrointestinal bleeding accounts for approximately 20% of emergency ... has been used as a first-line treatment option ... be used as a safe diagnostic and treatment ... refractory to endoscopic treatment. The incidence of rebleeding ...
... , , , VIENNA, ... Industries Ltd. (Nasdaq: TEVA ), today announced results ... corticosteroids (ICSs) in a "real-life" asthmatic population. The study ... to effectively treat both large and small airway inflammation, to ...
... , WASHINGTON, Sept. 16 Antidepressant drug ... year, has been known to cause birth defects, but the ... a Philadelphia court has heard. , , ... the drug and urged scientists to conceal Paxil,s risks. The ...
... , , BRAINTREE, Mass. and ... HAE ) announced today that it has signed a ... a cooperative of community blood centers. The contract provides ... of innovative blood management software products, including Prelude and Interlude, ...
... finds supervised exercise has better results , WEDNESDAY, Sept. ... shockwave treatment for relieving chronic shoulder pain, according to ... to treat shoulder pain, even though a number of ... Norwegian researchers studied 104 men and women, aged 18 ...
... , , WASHINGTON, Sept. ... Orthotic and Prosthetic Association today announced that Senators Tom Harkin ... Miller, and Lincoln Diaz-Balart are recipients of their joint organizations, ... view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/aopa/40117/ ...
Cached Medicine News:Health News:Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options 2Health News:Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options 3Health News:Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options 4Health News:Glaxo Official Memo Urged Scientists to Withhold Information About Paxil's Risks, Trial Hears; Pharmaceutical Industry Today Offers Complete News Coverage 2Health News:Haemonetics Signs Comprehensive Agreement with Blood Centers of America 2Health News:Shockwave Treatment May Not Be Best for Shoulder Pain 2Health News:Video: Members of Congress Receive Legislative Awards From National Amputee Organizations 2Health News:Video: Members of Congress Receive Legislative Awards From National Amputee Organizations 3
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
... Ophthalmics offers the most comprehensive family ... Instruments for Cataract incision, Glaucoma filtration, ... coagulation is achieved with minimal tissue ... Straight eraser styles are available in ...
Medicine Products: